HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events [ 2011 ] English Bernama : Cancer Cure Is Now In Malaysia

Monday21 May 2018

Bernama : Cancer Cure Is Now In Malaysia

Bernama

KUALA LUMPUR, Oct 24 (Bernama) -- There is a new hope for cancer patients in Malaysia.

A vaccine widely known for treating late-stage cancer -- almost all types of cancer, except leukemia -- is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV), which was only available in Japan previously, is able to completely destroy microscopic and tiny nests of cancer cells, thus preventing any future recurrences.

Discovered in 2005 by Dr Kenichiro Hasumi, a Japanese physician and researcher, HITV is an autologus (patient derived) active cell-based immunotherapy for metastatic or late-stage cancer patients.

It is based on immunology that harnesses human immune system's innate and adaptive ability to combat diseases.

Dr Hasumi, founder and chairman of Hasumi International Research Foundation in the United
States, has dedicated more than 40 years of his life to find a cure to cancer.

Speaking at a media conference Monday, Dr Hasumi said the therapy was highly effective for patients suffering from latestage cancer, when used in combination with radiotherapy.

"The use of tomotherapy (a type of radiation therapy) is important in this protocol. It can target the tumors precisely in one sweep, while reducing the radiation exposure to the
surrounding tissues," he said.

The treatment includes harvesting immune cells from the patient, culturing them
in the laboratory to become immature dentritic cells, and then re-introducing
them into the patient's body, through injection into the tumor.

Download
Source record here

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks